Hepatocellular carcinoma in patients co-infected with hepatitis C virus and human immunodeficiency virus

World Journal of Hepatology

Volumn 5, Issue 6, 2013, Pages 323-327

  Dimitroulis, Dimitrios ^a   Valsami, Serena ^b   Spartalis, Eleftherios ^a   Pikoulis, Emmanuel ^a   Kouraklis, Gregory ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Co infection; Hepatitis C virus; Hepatocellular carcinoma; Human immunodeficiency virus

Indexed keywords

EID: 84880829749     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i6.323     Document Type: Article

References (34)

1. Thomas DL. The challenge of hepatitis C in the HIV-infected person. Annu Rev Med 2008; 59: 473-485 [PMID: 18186707 DOI: 10.1146/annurev.med.59.081906.081110]
2. Singal AK, Anand BS. Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review. World J Gastroenterol 2009; 15: 3713-3724 [PMID: 19673011]
3. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831-837 [PMID: 11833007]
4. Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre-and post-HAART and the role of HCV coinfection. Hepatology 2004; 40: 115-119 [PMID: 15239093]
5. Monga HK, Rodriguez-Barradas MC, Breaux K, Khattak K, Troisi CL, Velez M, Yoffe B. Hepatitis C virus infectionrelated morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 33: 240-247 [PMID: 11418885]
6. Bollepalli S, Mathieson K, Bay C, Hillier A, Post J, Van Thiel DH, Nadir A. Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients. Sex Transm Dis 2007; 34: 367-370 [PMID: 17016234]
7. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860 [PMID: 9516219]
8. Hogg RS, Yip B, Kully C, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIVinfected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160: 659-665 [PMID: 10102000]
9. Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, Montaner JS. Improved survival among HIVinfected individuals following initiation of antiretroviral therapy. JAMA 1998; 279: 450-454 [PMID: 9466638]
10. Floridia M, Massella M, Bucciardini R, Perucci CA, Rossi L, Tomino C, Fragola V, Ricciardulli D, Galluzzo CM, Giannini G, Pirillo MF, Andreotti M, Mirra M, Vella S. Hospitalizations and costs of treatment for protease inhibitor-based regimens in patients with very advanced HIV-infection (CD4 & lt; 50/mm(3)). HIV Clin Trials 2000; 1: 9-16 [PMID: 11590493]
11. Ciuffreda D, Comte D, Cavassini M, Giostra E, Bühler L, Perruchoud M, Heim MH, Battegay M, Genné D, Mulhaupt B, Malinverni R, Oneta C, Bernasconi E, Monnat M, Cerny A, Chuard C, Borovicka J, Mentha G, Pascual M, Gonvers JJ, Pantaleo G, Dutoit V. Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication. Eur J Immunol 2008; 38: 2665-2677 [PMID: 18958874 DOI: 10.1002/eji.200838336]
12. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, Koziel MJ. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. Clin Infect Dis 2001; 33: 562-569 [PMID: 11462196]
13. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, Vidaud M, Bricaire F, Opolon P, Katlama C, Poynard T. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-1058 [PMID: 10498659]
14. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 2004; 164: 2349-2354 [PMID: 15557414]
15. García-Samaniego J, Rodríguez M, Berenguer J, Rodríguez-Rosado R, Carbó J, Asensi V, Soriano V. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-183 [PMID: 11197250]
16. Berenguer J, Alvarez-Pellicer J, Martín PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, Mallolas J, Sanz J, Tural C, Bellón JM, González-García J. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413 [PMID: 19575364 DOI: 10.1002/hep.23020]
17. Breitenstein S, Dimitroulis D, Petrowsky H, Puhan MA, Müllhaupt B, Clavien PA. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg 2009; 96: 975-981 [PMID: 19672926 DOI: 10.1002/bjs.6731]
18. Mauss S, Valenti W, DePamphilis J, DuffF, Cupelli L, Passe S, Solsky J, Torriani FJ, Dieterich D, Larrey D. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18: F21-F25 [PMID: 15316334]
19. Dimitroulis D, Valsami S, Stamopoulos P, Kouraklis G. Immunological HCV-associated thrombocytopenia: short review. Clin Dev Immunol 2012; 2012: 378653 [PMID: 22829850 DOI: 10.1155/2012/378653]
20. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, Morand P, Goujard C, Pialoux G, Piroth L, Salmon-Céron D, Degott C, Cacoub P, Perronne C. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-2848 [PMID: 15598915]
21. Bani-Sadr F, Lapidus N, Melchior JC, Ravaux I, Bensalem M, Rosa I, Cacoub P, Pol S, Perronne C, Carrat F. Severe weight loss in HIV/HCV-coinfected patients treated with interferon plus ribavirin: incidence and risk factors. J Viral Hepat 2008; 15: 255-260 [PMID: 18307589 DOI: 10.1111/j.1365-2893.2007.00939.x]
22. Laguno M, Milinkovic A, de Lazzari E, Murillas J, Martínez E, Blanco JL, Loncá M, Biglia A, Leon A, García M, Larrousse M, García F, Miró JM, Gatell JM, Mallolas J. Incidence and risk factors for mitochondrial toxicity in treated HIV/HCVcoinfected patients. Antivir Ther 2005; 10: 423-429 [PMID: 15918333]
23. Mira JA, López-Cortés LF, Merino D, Arizcorreta-Yarza A, Rivero A, Collado A, Ríos-Villegas MJ, González-Serrano M, Torres-Tortoso M, Macías J, Valera-Bestard B, Fernández-Fuertes E, Girón-González JA, Lozano F, Pineda JA. Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCVcoinfected patients. Antivir Ther 2007; 12: 1225-1235 [PMID: 18240862]
24. Vogel M, Ahlenstiel G, Hintsche B, Fenske S, Trein A, Lutz T, Schürmann D, Stephan C, Khaykin P, Bickel M, Mayr C, Baumgarten A, Buggisch P, Klinker H, John C, Gölz J, Staszewski S, Rockstroh JK. The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIVpositive Individuals. Eur J Med Res 2010; 15: 102-111 [PMID: 20452894]
25. Huang JF, Yu ML, Huang CF, Chiu CF, Dai CY, Huang CI, Yeh ML, Yang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Wang LY, Chuang WL. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies -a multicenter prospective trial. J Hepatol 2011; 54: 219-226 [PMID: 21056500 DOI: 10.1016/j.jhep.2010.07.011]
26. MacDonald DC, Nelson M, Bower M, Powles T. Hepatocellular carcinoma, human immunodeficiency virus and viral hepatitis in the HAART era. World J Gastroenterol 2008; 14: 1657-1663 [PMID: 18350596]
27. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34 [PMID: 19095497 DOI: 10.1016/S1470-2045(08)70285-7]
28. Keating GM, Santoro A. Sorafenib: a review of its use in advanced hepatocellular carcinoma. Drugs 2009; 69: 223-240 [PMID: 19228077 DOI: 10.2165/00003495-200969020-00006]
29. Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, Myers RP, Morlat P, Pialoux G, Pol S, Cacoub P. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-1809 [PMID: 12891066]
30. Norris S, Taylor C, Muiesan P, Portmann BC, Knisely AS, Bowles M, Rela M, Heaton N, O'Grady JG. Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection. Liver Transpl 2004; 10: 1271-1278 [PMID: 15376307]
31. NeffGW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, SchiffER, Shakil O, Fung JJ. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239-247 [PMID: 12619020]
32. Ragni MV, Belle SH, Im K, NeffG, Roland M, Stock P, Heaton N, Humar A, Fung JF. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-1420 [PMID: 14624365]
33. Clavien PA. Tenth Forum on Liver Transplantation: are HIV-infected patients candidates for liver transplantation. J Hepatol 2008; 48: 695-696 [PMID: 18331762 DOI: 10.1016/j.jhep.2008.02.007]
34. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int 2004; 66: 532-541 [PMID: 15253704]